Chemical Synthesis General Procedures. Chemicals for the syntheses described below were purchased from Aldrich and Acros, and used without further purification. NMR spectra were recorded with a Varian 400 spectrometer using a 1 H or 13 C solvent peak as internal reference (7.26 ppm for CHCl 3 and the CDCl 3 triplet at 77.26 ppm). Analytical thin-layer chromatography was performed with 0.25 mm E. Merck silica gel plates (60F-254) and visualized by dipping in a solution of KMnO 4 and heating. E. Merck silica gel 60 (particle size 0.040-0.063 mm) was used for column chromatography. All chemicals were obtained from Sigma and used as received. Solvents used were of the highest commercial grade available. Reactions were performed under inert atmosphere (N 2 ) with dry solvents under anhydrous conditions, unless otherwise indicated. Chemical shifts are reported in values relative to tetramethylsilane, and coupling constants (J) are reported in Hz. Abbreviations used are: s (singlet), d (doublet), t (triplet), m (multiplet).
Dihydroisoxazole Synthesis. The synthesis of dihydroisoxazole was performed as previously reported (Rohloff et al., 1992) . Briefly, a solution of 50% glyoxalic acid (30.4g, 0.205 mol) , and hydroxylamine hydrochloride (14.3 g, 0.205 mol) in water (50 mL) was stirred for 1 hour at room temperature. The solution was cooled on ice before the slow addition of NaOH (3.28, 0.410 mol) . Sodium monophosphate monobasic (49.2 g, 0.410 mol) was then added on ice. The reaction mixture was warmed up to room temperature before the drop-wise addition of neat bromine (21.1 mL, 0.410 mol). The solution was stirred for 12 hours before the addition of sodium bisulfite. The mixture was extracted with dichloromethane, dried over sodium sulfate, and concentrated by evaporation. The isolated product, dibromoformaldoxime, was reacted without any further purification with allylamine, as previously described (Rohloff et al., 1992) .
Compounds 3-7 were synthesized, as previously reported (Watts et al., 2006) . Briefly, 4-azidobenzyl alcohol was reacted with p-nitrophenyl choloroformate in methylene chloride and N-methylmorpholine to give the carbonate 2 after purification by flash chromatography. The carbonate was reacted with the methyl ester of the appropriate amino acid in DMF and N-methylmorpholine, yielding the expected 4-azidobenzyl carbamate. Methyl ester hydrolysis followed by EDCI coupling of the resulting acid to the (S)-isomer of the dihydroisoxazole gave the indicated compound as a final product after flash chromatography purification.
4Nitrophenyl 4azidobenzyl carbonate (2).
Commercially available 4-aminobenzyl alcohol was converted to 4-azidobenzyl alcohol in 90% yield as previously published. (Spletstoser et al., 2004) In brief, 4-azidobenzyl alcohol (1g, 6.70 mmol) was dissolved in DCM, and p-nitrophenyl chloroformate (2.69, 13.4 mmol) was added to the mixture under rapid stirring in an ice bath. Nmethylmorpholine (885 L, 8.05 mmol) was then added drop-wise and the solution was stirred on ice allowing it to warm up to room temperature. The reaction was stirred for 8 h then diluted with 40 ml of EtOAc and washed with saturated aqueous bicarbonate (2  10 mL) to remove some of pnitrophenol. The organic phase was dried over sodium sulfate and the product was purified using flash chromatography using a plug of anhydrous of potassium carbonate. The carbonate was eluted using 95/5 Hexanes/ethyl acetate to give the final product in a good yield (74%). 68, 152.63, 145.62, 141.18, 130.96, 130.82, 125.67, 125.64, 121.94, 119.57, 70.57. 4Nitrophenyl 4ethynylbenzyl carbonate (20). Commercially available 4-ethynylbenzyl alcohol (1 g, 7.57 mmol) was dissolved in dichloromethane, and pnitrophenyl chloroformate (3.044 g, 15.13 mmol) was added to the solution with stirring. The reaction mixture was stirred on ice before the addition of Nmethylmorpholine (998 L, 9.07 mmol). The reaction was stirred and allowed to warm up to room temperature for 8 h. The reaction was diluted with EtOAc and washed with a saturated bicarbonate solution. The organic phase was collected, dried over sodium sulfate, and concentrated under reduced pressure. The product was isolated and purified by flash chromatography using 90/10 Hexanes/Ethyl acetate (68%). 64, 152.63, 133.40, 132.75, 128.67, 125.46, 123.61, 122.12, 120.66, 78.40, 70.55. (S)-4-azidobenzyl-((3-Bromo-4,5-dihydroisoxazol-5-yl)methylamino)-3-(4-hydroxylphenyl)-1-oxopropan-2-yl-carbamate (3). This compound was synthesized using the same method described for the synthesis of 7. 
13
C NMR (101 MHz, Acetone) δ 172. 18, 156.44, 156.04, 139.49, 134.47, 137.74, 130.52, 129.69, 128.35, 119.14, 115.35, 80.65, 65.40, 57.11, 43.86, 41.59, 40.56, 36.96 (S)4azidobenzyl((3Bromo4,5dihydroisoxazol5yl)methylamino)3(1H indol3yl)1oxopropan2ylcarbamate (4). This compound was synthesized using the same method described for the synthesis of 7. (S)4azidobenzyl((3Bromo4,5dihydroisoxazol5yl)methylamino)3(5 hydroxy1Hindol3yl)1oxopropan2ylcarbamate (5). This compound was synthesized using the same method described for the synthesis of 7. 86, 156.13, 151.12, 139.77, 137.80, 134.46, 131.61, 129.79, 128.61, 124.54, 119.17, 112.09, 111.85, 109.66, 102.97, 80.55, 65.49, 56.29, 43.82, 41.54 
(S)-4-azidobenzyl 2-((((S)-3-bromo-4,5-dihydroisoxazol-5-yl)methyl)carbamoyl) pyrrolidine-1-carboxylate (7).
Commercially available proline methyl ester (739 mg, 5.72 mmol) was dissolved in DMF (57 ml), and compound 2 (2.158 g, 6.87 mmol) was added under stirring. N-methylmorpholine (1.89 ml, 17.16 mmol) was added to the mixture. The reaction was stirred overnight, then diluted with EtOAc 50 mL, and washed with saturated solution of bicarbonate (3  25mL). The organic phase was dried over sodium sulfate and evaporated to dryness. The compound was purified via flash chromatography purification and isolated in a good yield (67%). The methyl ester product was then dissolved in (12 ml) of THF, and 1 equiv of LiOH was added as a 1M solution in water. Methanol was added in a drop-wise fashion until the mixture became homogenous. The reaction was stirred for 4 hours, and followed by TLC till completion. The reaction mixture was acidified and diluted with EtOAc and extracted three times, washed with brine, dried over sodium sulfate, and concentrated to dryness (95%). The acid was carried to the next step reaction without any purification. The acid (374 mg, 1.29 mmol) was dissolved in DMF (12.5 mL), HOBT (174 mg, 1.29 mmol) and EDCI (246 mg, 1.29 mmol) were added to the reaction mixture. The reaction was stirred for 12 h, then diluted with EtOAc, and washed with brine (3  10mL). The organic phase was dried over sodium sulfate and concentrated to dryness. The final product was purified and isolated after flash chromatography in a good yield (73%). 25, 154.63, 147.16, 129.79, 129.57, 126.19, 119.00, 80.61, 65.99, 60.48, 60.18, 47.39, 46.91, 41.77, 41.13, 24.72, 23.48 (S)-4-Ethynyl benzyl-((3-Bromo-4,5-dihydroisoxazol-5-yl)methylamino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl-carbamate (9) . This compound was synthesized using the method described for the synthesis of 6. 1 H NMR (400 MHz, Acetone) δ 10.42 (s, 1H), 7.61 (d, J = 7.8 Hz, 1H), 7.40 (dd, J = 16.7, 7.9 Hz, 4H), 7.27 (m, J = 7.7 Hz, 3H), 7.07 (t, J = 7.5 Hz, 1H), 6.98 (t, J = 7.5 Hz, 1H), 6.82 (d, J = 7.6 Hz, 1H), 5.01 (s, 2H), 4.68 (m, 1H), 4.48 (m, 1H), 3.67 (s, 1H), 3.51 (m, 1H), 3.33 (m, 3H), 3.14 (m, 2H).
13
C NMR (101 MHz, Acetone) δ 173. 41, 163.20, 156.35, 138.26, 136.90, 132.12, 127.83, 126.22, 124.13, 121.61, 118.80, 115.96, 111.67, 110.20, 83.37, 80.43, 78.99, 65.65, 56.45, 54.41, 43.79, 41.64, 36.02, 30.81, 20.43 
(S)-4-Ethynyl benzyl-((3-Bromo-4,5-dihydroisoxazol-5-yl)methylamino)-3-(5-fluoro-1H-indol-3-yl)-1-oxopropan-2-yl-carbamate (11).
This compound was synthesized using the same method described for the synthesis of 6. S)-3-bromo-4 ,5-dihydroisoxazol-5-yl)methyl)carbamoyl) pyrrolidine-1-carboxylate (12). This compound was synthesized using the same method described for the synthesis of 6. 1 H NMR (400 MHz, Acetone) δ 8. 24 -8.07 (m, 1H), 7.55 -7.29 (m, 2H), 7.17 -6.97 (m, 1H), 5.14 (m, 2H), 4.87 -4.66 (m, 2H), 4.31 (m, 2H), 3.67 (s, 1H), 3.62 -3.23 (m, 5H) , 3.18 -3.00 (m, 1H), 2.02 (m, 1H), 1.94 (m, 2H).
(S)-4-ethynylbenzyl 2-((((

13
C NMR (101 MHz, Acetone) δ 173. 28, 162.15, 139.95, 132.15, 126.19, 115.90, 83.54, 80.70, 78.73, 65.81, 61.10, 60.49, 47.44, 46.94, 43.85, 41.81, 35.52, 31.72, 30.21, 24.40 . ESI (MS): calcd for C 19 H 20 BrN 3 O 4 Na, 456.06; found, 456.1.
Synthesis of 22 was preformed according to a previously published procedure (Hannoush and Arenas-Ramirez, 2009 ) (See Figure S1-B) .
Synthesis of 24 was preformed according to a previously published procedure (Speers and Cravatt, 2004 ) (See Figure S1-B) .
Biological Assays
Figure S2 related to Table 2.
Titration of 6 and 16 against TG2 in a fibroblast monolayer. A) Titration of 6 against TG2 in a fibroblast wound model. TG2 activity was visualized after scratching a confluent WI-38 monolayer with a small pipette tip. Significant TG2 activity was detected around the wound in the presence of 300 M 5BP and vehicle (DMSO) (a-c). Moderate inhibition of TG2 was observed after activation in the presence of 3.1 M 6 (df). Complete inhibition of active TG2 was observed in the presence 12.5 M 6 (m-r). (a, d, g, j, m, p) Fibronectin (green) was visualized by staining with rabbit anti-fibronectin antibody, followed by Alexa fluor 488 conjugated goat anti-rabbit secondary antibody. (b, e, h, k, n, q) TG2 activity was visualized using Alexa Fluor 555 conjugated streptavidin (red). (e, f, i, l, o, r) Overlays. Scale bar represents 200 m and applies to all panels. B) Titration of 16 against TG2 in a fibroblast monolayer. TG2 activity was visualized after scratching a confluent WI-38 monolayer with a small pipette tip. Significant TG2 activity was detected around the wound in the presence of 300 M 5BP and vehicle (DMSO) (a-c). Moderate inhibition of TG2 was observed after activation in the presence of 3.1 M 16 (d-f). Complete inhibition of active TG2 was observed in the presence 6.25 M 16 (m-r). (a, d, g, j, m, p) Fibronectin (green) was visualized by staining with rabbit anti-fibronectin antibody, followed by Alexa fluor 488 conjugated goat anti-rabbit secondary antibody. (b, e, h, k, n, q) TG2 activity was visualized using Titration of 15 and 14 against TG2 in a fibroblast monolayer. A) Titration of 15 against TG2 in a fibroblast wound model. TG2 activity was visualized after scratching a confluent WI-38 monolayer with a small pipette tip. Significant TG2 activity was detected around the wound in the presence of 300 M 5BP and vehicle (DMSO) (a-c). Moderate inhibition of TG2 was observed after activation in the presence of 25 M 15 (d-f). Complete inhibition of active TG2 was observed in the presence of 75 M 15 (mr). (a, d, g, j, m, p) Fibronectin (green) was visualized by staining with rabbit antifibronectin antibody, followed by Alexa fluor 488 conjugated goat anti-rabbit secondary antibody. (b, e, h, k, n, q) TG2 activity was visualized using Alexa Fluor 555 conjugated streptavidin (red). (e, f, i, l, o, r) Overlays. Scale bar represents 200 m and applies to all panels. B) Titration of 14 against TG2 in a fibroblast wound model. TG2 activity was visualized after scratching a confluent WI-38 monolayer with a small pipette tip. Significant TG2 activity was detected around the wound in the presence of 300 M 5BP and vehicle (DMSO) (a-c). Moderate inhibition of TG2 was observed after activation in the presence of 25 M 14 (d-f). Complete inhibition of active TG2 was observed in the presence of 75 M 14 (m-r). (a, d, g, j, m, p) Fibronectin (green) was visualized by staining with rabbit anti-fibronectin antibody, followed by Alexa fluor 488 conjugated goat anti-rabbit secondary antibody. (b, e, h, k, n, q) TG2 activity was visualized using Alexa Fluor 555 conjugated streptavidin (red). (e, f, i, l, o, r) Overlays. Scale bar represents 200 m and applies to all panels. Kinetic Analysis of TG2. Although the physiological reaction catalyzed by TG2 is a transamidation reaction, our assay monitored the deamidation of a glutamine residue in a peptide substrate to a glutamate residue. This activity was measured via a coupled assay, where glutamate dehydrogenase (GDH; Biozyme, San Diego, CA) catalyzed the reductive amination of -ketoglutarate using the ammonium ion released from the TG2-catalyzed deamidation. Concomitant oxidation of NADH to NAD + was monitored spectrophotometrically at 340 nm. The overall reaction is as follows:
The standard assay, optimized for human TG2, utilized the following freshly prepared stock solutions: (1) MOPS buffer solution: a 5 × stock of 200 mM MOPS, 5 mM CaCl 2 , 1 mM Na 4 EDTA, and 10 mM -ketoglutarate (pH 7.2); (2) NADH stock solution: 1.25 mM NADH; (3) GDH stock solution: 0.25 units of GDH/l in a MOPS buffer; and (4) 300 mM benzyloxycarbonyl-glutaminyl-glycine (Z-Gln-Gly; Sigma) in water. 100 l of the NADH stock solution was combined with 64 l of the MOPS buffer solution, 36 l of the GDH stock solution, and a specified amount of Z-Gln-Gly. Water was added to a final volume of 420 l. The reaction was initiated by adding TG2, and NADH consumption was monitored at RT for 1h. The progress curves were fitted to the
